bodyType

customContents

entityId

entityUuid

articlePageQuery

filter

article

articleBaseAdvertisingInfoArticle

articleListArticle

articleSeoArticle

helpersCheckIsPostiesArticle

hooksArticleAcknowledgementGateOverlayArticle

hooksTrackPageViewArticle

hooksContentInterestArticle

articleLinkingDataContent

hooksAmpRedirectArticle

articleSchemaContent

liveArticle

advertZone

sentiment

contentLock

topics

types

sections

moreOnThisArticles

urlAlias

commentCount

authorLocations

authors

paywallTypes

corrections

sponsorType

displaySlideShow

multimediaEmbed

printHeadline

seriesContainer

socialHeadline

headline

flag

firstTopic

glossary

flattenTypeIds

publishedDate

additionalInfoBoxes

images

image

relatedLinks

relatedNewsletters

__typename

createdDate

sponsor

pdfFiles

seriesReverseOrder

series

disableOffPlatformContent

published

updatedDate

summary

subHeadline

body

keywords

readingTime

customTimezone

liveContents

Reuters

US authorities are investigating British drugmaker GlaxoSmithKline for violations of US anti-bribery laws in China after Chinese government officials accused the company of bribing doctors, three sources familiar with the probe said last week.
The sources did not want to be identified because the matter is not public.
The investigation is part of a wider probe of drugmakers' sales practices in China, said one of the sources, adding that the Department of Justice (DOJ) has expanded a probe into GSK's business practices in other countries to include the Chinese bribery allegations.
A company spokesman on Friday confirmed the new line of inquiry in response to questions from Reuters.
"Since the investigation in China began, we have proactively reached out to relevant regulators. This includes the DOJ, and we have been in an ongoing dialogue with them," said David Mawdsley, a spokesman for GSK in London.
Chinese police said in July they had detained four Chinese executives at GSK on allegations the executives funneled up to 3 billion yuan (HK$3.8 billion) ) to travel agencies to facilitate bribes to doctors to boost the sale of its medicines.
The US Justice Department's probe is focusing on whether GSK and other drugmakers violated the US Foreign Corrupt Practices Act, which forbids US companies from engaging in bribery while doing business abroad.
Although GSK is a British company, US law enforcement officials have jurisdiction over it because its shares are listed on a US stock exchange. GSK's American depository receipts trade on the New York Stock Exchange.
Justice Department officials have been investigating GSK's sales practices in other countries for at least three years, according to the company's corporate filings. Expanding the probe to include China is a routine step, experts said on Friday.
GSK, which has not yet been subpoenaed on the China case, has said some of its senior Chinese executives appear to have broken the law.
The company said in July it believes the alleged corruption involved senior Chinese staff working around its systems to potentially defraud the company, as well as cheating the Chinese healthcare system.
The company added that GSK's head office had no knowledge of the situation.


FDA approves GSK vaccine to combat meningococcal infections

WHO recommends malaria vaccine for children, to be rolled out next year

The future of Covid-19 vaccines? Why nasal sprays, not needles, could be better in the long run

GlaxoSmithKline to manufacture Novavax Covid-19 vaccine in UK, securing local supply

GlaxoSmithKline

US investigating bribery involving GlaxoSmithKline in China

News

China

Business

Companies

Allegations include bribery of doctors by company officials on the mainland


US authorities are investigating British drugmaker GlaxoSmithKline for violations of US anti-bribery laws in China after Chinese government officials accused the company of bribing doctors, three sources familiar with the probe said last week.
